C
Calidi Biotherapeutics, Inc. (CLDI)
ASE – Real Time Price. Currency in USD
0.18
-0.01 (-6.80%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
ASE – Real Time Price. Currency in USD
0.18
-0.01 (-6.80%)
At close: May 12, 2026, 4:00 PM EDT
Revenue breakdown data has not been calculated yet.
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 1.59 | 6.05 | 8.0 | |
| Quick ratio | 1.59 | 5.63 | 8.0 | |
| Debt to Equity | 0.68 | 0.30 | 7.0 | |
| Debt to Assets | 0.29 | 1.04 | 7.0 | |
| Interest coverage | -106.33 | -16.91 | 1.0 | |
| Weighted average score | 6.2 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 45K | N/A | N/A | N/A | N/A |
| Gross Profit | -229K | -1M | -2M | -2M | -2M |
| Operating Income | -23M | -29M | -22M | -20M | -20M |
| Net Income | -25M | -29M | -22M | -26M | -26M |
| EBITDA | -23M | -28M | -20M | -19M | -19M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | N/A | 1.0 |
| Next quarter | N/A | N/A | 1.0 |
| Current year | N/A | 7.23 | 3.0 |
| Next year | N/A | 13.04 | 4.5 |
| Weighted average score | 2.4 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | 62.52 | 74.21 | -18.93 | 7.8 |
| Y/Y | 999 | 1 | 82.41 | 6.54 | 6.8 |
| 3y average | 632.67 | -2.05 | 83.07 | -27.39 | 5.5 |
| 5y average | N/A | N/A | N/A | N/A | 1.0 |
| Weighted average score | 5.3 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Company's cash reserves $5.7M significantly exceed its total debt $2.6M, ensuring strong financial flexibility
Total current assets $6.3M exceed Total current liabilities $3.9M, highlighting excellent liquidity
Debt-to-equity ratio (0.7) is well below the industry average (0.3), showcasing prudent financial management
Interest coverage ratio (-106.3x) is dangerously low, suggesting debt repayment risks
Negative free cash flow -$5.1M limits the company's ability to reinvest or pay down debt